Pidotimod NEW

Clinical application

Suitable for immunocompromised patients. It can be used for the adjuvant treatment of recurrent respiratory tract infection, ear, nose and throat infection, urinary and reproductive system infection, and other chronic diseases such as viral infection and malignant tumor.

Pharmacokinetics

This product is absorbable orally with a bioavailability of 45%, and food can affect the absorption of this product. The blood concentration reached the peak 2 hours after oral administration. The binding rate of plasma protein is very low, it is not metabolized in the body, and almost all of it is excreted from the urine as the original drug, with a half-life of 4 hours. The physicochemical properties, synthetic methods, clinical applications and adverse reactions of pidotimod were discussed.

Matters needing attention

1. Use with caution those with high sensitivity.

2. There is no information on the use of drugs for pregnant and lactating women, so it is not suitable for pregnant and lactating women.

3. Strictly follow the usage and dosage of children's medication. No application for children under 2 years old has been reported.

4. There is no systematic clinical research data on elderly drug use.

5. There have been no reports of drug overdose with this product. In case of drug overdose, it is necessary to use conventional methods such as emesis, catharsis, infusion, etc., to promote the discharge of excess drugs.

Drug interaction

Avoid taking this medicine with meals. Take it before or 2 hours after a meal.